396 related articles for article (PubMed ID: 30259911)
1. Predictive markers in lung cancer: a few hints for the practicing pathologist.
Barbareschi M; Barberis M; Buttitta F; Doglioni C; Fiorentino M; Fontanini G; Franco R; Marchetti A; Rossi G; Troncone G
Pathologica; 2018 Mar; 110(1):29-38. PubMed ID: 30259911
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization.
Luk PP; Selinger CI; Mahar A; Cooper WA
Arch Pathol Lab Med; 2018 Aug; 142(8):922-928. PubMed ID: 29902067
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1.
Lee J; Park CK; Yoon HK; Sa YJ; Woo IS; Kim HR; Kim SY; Kim TJ
Thorac Cancer; 2019 Jan; 10(1):103-110. PubMed ID: 30475455
[TBL] [Abstract][Full Text] [Related]
4. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
Ginestet F; Lambros L; Le Flahec G; Marcorelles P; Uguen A
Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706
[TBL] [Abstract][Full Text] [Related]
6. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
[TBL] [Abstract][Full Text] [Related]
7. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
8. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Garrido P; Conde E; de Castro J; Gómez-Román JJ; Felip E; Pijuan L; Isla D; Sanz J; Paz-Ares L; López-Ríos F
Clin Transl Oncol; 2020 Jul; 22(7):989-1003. PubMed ID: 31598903
[TBL] [Abstract][Full Text] [Related]
9. Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples.
Yao Y; Peng M; Shen Q; Hu Q; Gong H; Li Q; Zheng Z; Xu B; Li Y; Dong Y
Thorac Cancer; 2019 Feb; 10(2):193-202. PubMed ID: 30565433
[TBL] [Abstract][Full Text] [Related]
10. [Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
López-Ríos F; Paz-Ares L; Sanz J; Isla D; Pijuan L; Felip E; Gómez-Román JJ; de Castro J; Conde E; Garrido P
Rev Esp Patol; 2020; 53(3):167-181. PubMed ID: 32650968
[TBL] [Abstract][Full Text] [Related]
11. Cytology samples and molecular biomarker testing in lung cancer-advantages and challenges.
Canberk S; Engels M
Virchows Arch; 2021 Jan; 478(1):45-57. PubMed ID: 33389149
[TBL] [Abstract][Full Text] [Related]
12. Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.
Clavé S; Rodon N; Pijuan L; Díaz O; Lorenzo M; Rocha P; Taus Á; Blanco R; Bosch-Barrera J; Reguart N; de la Torre N; Oliveras G; Espinet B; Bellosillo B; Puig X; Arriola E; Salido M
Clin Lung Cancer; 2019 Jul; 20(4):e421-e429. PubMed ID: 30898567
[TBL] [Abstract][Full Text] [Related]
13. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.
Ekin Z; Nart D; Savaş P; Veral A
Balkan Med J; 2021 Sep; 38(5):287-295. PubMed ID: 34558414
[TBL] [Abstract][Full Text] [Related]
14. Molecular diagnosis in non-small-cell lung cancer: expert opinion on
Conde E; Rojo F; Gómez J; Enguita AB; Abdulkader I; González A; Lozano D; Mancheño N; Salas C; Salido M; Salido-Ruiz E; de Álava E
J Clin Pathol; 2022 Mar; 75(3):145-153. PubMed ID: 33875457
[TBL] [Abstract][Full Text] [Related]
15. The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay.
Evans M; O'Sullivan B; Hughes F; Mullis T; Smith M; Trim N; Taniere P
Pathol Oncol Res; 2020 Jan; 26(1):79-89. PubMed ID: 30225784
[TBL] [Abstract][Full Text] [Related]
16. Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?
Rossi G; Ragazzi M; Tamagnini I; Mengoli MC; Vincenzi G; Barbieri F; Piccioli S; Bisagni A; Vavala T; Righi L; Novello S; Gelsomino F; Tiseo M
Curr Drug Targets; 2017; 18(1):13-26. PubMed ID: 25901525
[TBL] [Abstract][Full Text] [Related]
17. Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer.
Zhao J; Zhou J; Chen Z; Wang B; Zhang X; Zhou J; Ding W
Int J Clin Exp Pathol; 2015; 8(3):3344-8. PubMed ID: 26045865
[TBL] [Abstract][Full Text] [Related]
18. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
Rogers TM; Russell PA; Wright G; Wainer Z; Pang JM; Henricksen LA; Singh S; Stanislaw S; Grille J; Roberts E; Solomon B; Fox SB
J Thorac Oncol; 2015 Apr; 10(4):611-8. PubMed ID: 25789833
[TBL] [Abstract][Full Text] [Related]
19. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
20. ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.
Pisapia P; Lozano MD; Vigliar E; Bellevicine C; Pepe F; Malapelle U; Troncone G
Cancer Cytopathol; 2017 Nov; 125(11):817-830. PubMed ID: 28743163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
